Surrozen (SRZN) Liabilities and Shareholders Equity (2020 - 2026)
Surrozen (SRZN) recorded quarterly Liabilities and Shareholders Equity of $120.7 million in Q1 2026, up 22.27% quarter-over-quarter from $98.7 million in Q4 2025, and up 5.12% on a YoY basis from $114.8 million in Q1 2025.
Surrozen (SRZN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Surrozen's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $120.7 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 5.12% year-over-year to $120.7 million; the TTM figure through Mar 2026 stood at $416.2 million (up 62.34% YoY), while the FY2025 annual figure was $98.7 million, up 103.7% from the prior year.
- Liabilities and Shareholders Equity was $120.7 million for Q1 2026 at Surrozen, up from $98.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $120.7 million in Q1 2026 to a low of $36.7 million in Q1 2024.
- Historically, Liabilities and Shareholders Equity has averaged $79.4 million across 5 years, with a median of $89.4 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity tumbled 50.52% in 2024, then soared 212.75% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $89.4 million in 2022, then plunged by 48.48% to $46.1 million in 2023, then grew by 5.18% to $48.5 million in 2024, then surged by 103.7% to $98.7 million in 2025, then rose by 22.27% to $120.7 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $120.7 million (Q1 2026), $98.7 million (Q4 2025), and $94.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 640.56 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 120.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 120.71 Mn |
| Dec 31, 2025 | 98.73 Mn |
| Sep 30, 2025 | 94.05 Mn |
| Jun 30, 2025 | 102.70 Mn |
| Mar 31, 2025 | 114.83 Mn |
| Dec 31, 2024 | 48.47 Mn |
| Sep 30, 2024 | 48.00 Mn |
| Jun 30, 2024 | 45.07 Mn |
| Mar 31, 2024 | 36.72 Mn |
| Dec 31, 2023 | 46.08 Mn |
| Sep 30, 2023 | 53.97 Mn |
| Jun 30, 2023 | 64.00 Mn |
| Mar 31, 2023 | 74.20 Mn |
| Dec 31, 2022 | 89.44 Mn |
| Sep 30, 2022 | 91.43 Mn |
| Jun 30, 2022 | 104.13 Mn |
| Mar 31, 2022 | 117.66 Mn |
| Dec 31, 2021 | 137.17 Mn |
| Sep 30, 2021 | 150.64 Mn |
| Jun 30, 2021 | 92.95 Mn |